Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: BNC210 in PTSD
NCT02933606Phase 2Completed
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of soclenicant in post-traumatic stress disorder (PTSD) (4 arms), sponsored by Neuphoria Therapeutics Inc. Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 Total Symptom Severity Score at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
soclenicant
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT02933606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933606.